Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Freenome
259 East Grand Avenue, Suite 3434
South San Francisco, CA 94080
Phone: 831-704-6883

Freenome is a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection. By combining a deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, Freenome is developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Examples of Freenome’s novel research include advancing the fields understanding of using machine learning for early stage colorectal cancer detection featured at Digestive Disease Week and using cfDNA fragment coverage to predict gene expression featured at American Association for Cancer Research’s Annual Meeting.

Key Contact
Name
Gabriel Otte
Title
CEO and Co-Founder
Funding Events

Date
Amount
Type
Investors
Valuation
06/09/16 $5,500,000 Seed Data Collective
Founders Fund
Third Kind Venture Capital
undisclosed
03/01/17 $65,000,000 Series A Charles River Ventures
Data Collective
Founders Fund
Innovation Endeavors
Polaris Partners
Spectrum 28
undisclosed
08/28/17 $7,000,000 Series A Extension Anne Wojcicki
Section 32
undisclosed
07/24/19 $160,000,000 Series B BrightEdge Ventures
Data Collective
Google Ventures
Kaiser Permanente Ventures
Perceptive Advisors
Polaris Partners
RA Capital Management
Roche Venture Fund
Section 32
T. Rowe Price Associates
Verily Life Sciences
undisclosed
08/26/20 $270,000,000 Series C Bain Capital Life Sciences
Catalio Capital Management
Colorectal Cancer Alliance
Cormorant Asset Management
EcoR1 Capital
Farallon Capital Management
Fidelity Management & Research Company
Janus Henderson Investors
Perceptive Advisors
Rock Springs Capital
undisclosed
12/07/21 $300,000,000 Series D A16z
Artis Ventures
Bain Capital Life Sciences
BrightEdge Ventures
Catalio Capital
Cormorant Capital
DCVC
Farallon Capital Management
Fidelity Management & Research Company
GV
Perceptive Advisors
RA Capital Management
undisclosed
01/11/22 $290,000,000 Venture Roche Venture Fund
undisclosed


Featured Reading